I collect gold fingers in the heavens

Not just US stocks.

In fact, the stocks of medical companies around the world have been affected, whether they have anti-cancer business or not.

Medical stocks around the world are falling.

However, [Four-Armed King Kong] easily made 200 billion U.S. dollars in profits and returned them to China.

Of course, 200 billion US dollars is not much.

It is not as big as Wu Siyuan's profit of hundreds of billions of dollars from shorting US stocks before.

But this [not much] depends on who you compare with.

200 billion US dollars is enough to be on the [Forbes Rich List].

His eyes turned back to the country.

Because of [Redikumab], the heat is getting bigger and bigger (harvesting is over).

[Xuanhu Technology] has finally stood up and announced the results of clinical trials that have only been conducted for more than a month to the outside world.

Anticancer drugs mainly look at several indicators - OS, PFS, ORR.

Tumor OS refers to the overall survival time of cancer patients.

OS is the acronym for Overall Surviva in English. In randomized controlled studies, tumor OS refers to the time from randomization to patient death due to any cause.

Tumor OS data are often considered to be the best efficacy judging endpoints in tumor-related clinical trials.

In clinical research, if it is proved that a new drug has cracked overall survival, it is often more meaningful than other research endpoints.Only a drug that can finally prove to prolong overall survival can finally change the treatment practice and modify the current clinical guidelines.

In other words, in order to judge whether a new anti-tumor drug is effective and how much benefit it can bring to patients, the prolongation of overall survival time is the last word and the gold standard. Final requirements for new oncology drugs.

After anti-tumor therapy, the acquisition of patient OS often requires long-term follow-up of large sample populations.

Of course, [Xuanhu Technology]'s [Radidex] experiment has only been more than a month now, and the OS can't see anything.

Then there is PFS!

PFS is one of the indicators for judging the survival rate of malignant tumors in patients with malignant tumors.

PFS refers to the progression-free survival time, which can be used to judge the efficacy of drugs in tumor treatment, and can be used as the primary or secondary endpoint of clinical drug development trials.

It usually refers to the time between the initiation of treatment and the progression or death of patients with malignant tumors.

Sometimes, PFS is used together with overall survival time as an index to evaluate the efficacy of antineoplastic drugs.

This data requires long-term experimental time to produce more meaningful results.

The experimental time of [Redikumab] was only more than one month.

There are many cases where cancer cells cannot be detected in the body, but with the current level of technology in the real world, it is still impossible to guarantee whether all the cancer cells in the cases have been eliminated.

So this PFS is also unable to come up with accurate data.

Again, the clinical trial is too short, and a lot of data cannot be counted.

Another one is ORR!

Tumor ORR refers to the objective response rate. Academically, it refers to the proportion of patients whose tumor volume has shrunk by 30% and can be maintained for more than 4 weeks, that is, the sum of the proportion of complete remission (CR) and partial remission (PR). The higher the ORR, the more More patients achieved tumor shrinkage with this treatment.

In layman's terms, it is the proportion of patients who are effective after receiving a certain treatment. The higher the ORR, the more patients with tumor shrinkage using this treatment.

The intuitive way to see whether a patient’s treatment is effective is to see whether the tumor has shrunk and how much it has shrunk. Of course, the ideal situation is that the tumor disappears after taking the medicine.

If the tumor still grows by more than 20% after treatment or a new mass appears, this treatment plan has failed; if the tumor shrinks by more than 30%, and the re-examination after 4 weeks still shrinks by more than 30%, it means that the treatment is effective.

ORR reflects the probability of tumor shrinkage or elimination after tumor drug treatment. For example, ORR=20% means that 20% of patients have completely or partially disappeared tumors after treatment.

However, ORR has a flaw, that is, it reflects the efficacy results of each treatment evaluation point, and cannot answer the patient's entire efficacy benefit process, such as prolonging the life span of several months, so other indicators are needed to supplement it.

ORR data is currently one of the few data that [Xuanhu Technology] can provide to the outside world.

And this data is 100%!

Yes, the objective sustained release rate of [Redikumumab] is 100%.

Join the experimental group and get the real [Redikumumab] instead of the placebo for various types of advanced cancer patients, the objective sustained release rate of [Redikumab] is 100%.

Moreover, what is even more exaggerated is that one month after taking [Redirimumab], the tumor shrinkage effect was the worst, reaching more than 60.00%, and according to the latest test results, the tumor area is still shrinking Among them, whether it is the original tumor lesion or the metastatic lesion.

Among them, the tumors of the few patients with the best results could no longer be detected. After supplementing nutrition, their bodies looked no different from ordinary people. Of course, the permanent damage caused by the tumors to some organs of the body was not It can no longer be recovered.

…………………………………………………………………………………………………………………………………… ...........

[Xuanhu Science and Technology] The ORR data is mainly released to the public:

All experimenters who were not members of the placebo group responded with an objective sustained release rate of [-]%.

At the same time, a few more words were announced:

[Redikumumab] All participants responded to all types of cancer.

No side effects have been found so far.

Preliminary efficacy analysis is very encouraging!
……………………………………………………………………………………………………………………………………… ……

[Xuanhu Technology] After the official news came out.

The global public opinion field exploded.

All eyes of the world are on here.

It's not just eyes here.

Cancer patients all over the world, especially those with advanced cancer, are frantically applying to enter China, requesting the supply of [Redirimumab].

The International Health Organization attaches great importance to this matter and has sent a large number of officials to intervene.

This is no longer a simple medical matter, but has risen to the political level.

Huaguo naturally attaches great importance to it.

Of course, what makes them pay attention is the domestic situation.

After [Xuanhu Technology] announced this [clinical data], many cancer patients in China also looked crazy.

It wasn't sure before, but now it's official.

They tried every means to obtain the anti-cancer [Radirumab], no, it should be said to be [the magic drug for cancer treatment]!
Especially those terminally ill cancer patients and their families are crazy.

Because patients in the terminal stage are really racing against the god of death every day. For some unknown reason, when tumor complications occur, the person is gone.

They desperately want to get this drug sooner.